Outcome of Board Meeting held today, i.e. 09th June, 2026 for approval of financials results for the half year and year ended 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Goldline Pharmaceutical Limited's Board approved audited standalone financial results for FY26 (year ended 31 March 2026) at its meeting on 9 June 2026. Revenue from operations grew to ₹3,119.76 lakhs from ₹2,805.57 lakhs in FY25, an increase of about 11.2%. Profit after tax jumped to ₹411.71 lakhs from ₹283.43 lakhs, a growth of around 45.3%, with EPS rising to ₹5.97 from ₹4.11. The company also appointed M/s. Kunal Dutt & Associates as Internal Auditor from FY27. The company recently got listed on the BSE SME platform on 19 May 2026, shortly after the reporting period. The auditor issued an unmodified opinion with an emphasis of matter noting the recent listing.
Strong PAT growth of ~45% on moderate revenue growth signals healthy margin expansion, which is positive for shareholders. The recently listed SME status (May 2026) means this is the company's first reported full-year results post-listing, providing initial visibility into the business.